An analysis from the U.K. finds an improvement in mortality, with invasive treatment strategies responsible for much of the gain.
The decline in mortality among patients with non–ST-elevation myocardial infarction (NSTEMI) in Western countries is well documented, but the contributing factors are not clear. To investigate changes in mortality, patient population, and treatments, investigators used a database of detailed clinical information on nearly 400,000 patients from 247 hospitals in England and Wales.
The number of patients hospitalized dropped from 67,441 in 2003–2004 to 56,649 in 2012–2013. Demographics during both periods were similar (median age, about 72; male, about 60%). The percentage at intermediate to high risk decreased from 87% to 82%. Median total cholesterol dropped from 193 to 178 mg/dL.
Use of treatments varied over time. Pre-admission, aspirin incr…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association